COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
Since the original emergency use authorization was issued in August 2020, new data has prompted this change to convalescent plasma use.
Key highlights of H.R.7663 impact on telehealth regulations.
Travel within the United States may require negative COVID-19 result if CDC implements contemplated changes.
Changes to US Food and Drug Administration’s (FDA) Discontinuance List makes reporting more useful for clinical laboratories.
Creation of COVID-19 Pandemic Testing Board may affect clinical laboratories and lead to a change in national COVID-19 testing.
Thirty-one pages of new CMS guidance distilled into 10 probing questions revealing what CMS surveyors will be looking for in clinical laboratories, with regard to their COVID-19 testing tracing and reporting.
Since the original emergency use authorization was issued in August 2020, new data has prompted this change to convalescent plasma use.
Key highlights of H.R.7663 impact on telehealth regulations.
Travel within the United States may require negative COVID-19 result if CDC implements contemplated changes.
Changes to US Food and Drug Administration’s (FDA) Discontinuance List makes reporting more useful for clinical laboratories.
Creation of COVID-19 Pandemic Testing Board may affect clinical laboratories and lead to a change in national COVID-19 testing.
Thirty-one pages of new CMS guidance distilled into 10 probing questions revealing what CMS surveyors will be looking for in clinical laboratories, with regard to their COVID-19 testing tracing and reporting.
